Scott Thomas Jackson - 05 Dec 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 Dec 2025, 09:01:56 UTC
Prior SEC filing
16 Jun 2025
Next SEC filing
20 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Thomas Jackson

Key filing fact

Scott Thomas Jackson filed Form 4 for Mural Oncology plc (MURA) on 05 Dec 2025.

Key facts

  • This page summarizes Scott Thomas Jackson's Form 4 filing for Mural Oncology plc (MURA).
  • 3 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 05 Dec 2025, 09:01.

Change

  • Previous filing in this sequence was filed on 16 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001566617 Primary reporting owner

Jackson Scott Thomas

Relationship
Director
Address
C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
Signature
/s/ Scott Thomas Jackson
Signature date
05 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-8,637
Change %
-100%
Price
Shares after
0
Date
05 Dec 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
8,637
Exercise price
$2.56
Footnotes
F1, F2
MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-8,462
Change %
-100%
Price
Shares after
0
Date
05 Dec 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
8,462
Exercise price
$3.35
Footnotes
F2
MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-15,021
Change %
-100%
Price
Shares after
0
Date
05 Dec 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
15,021
Exercise price
$3.61
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Scott Thomas Jackson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

Footnote F2

Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .